Use of Cryopreserved Cadaver Vein Allograft (CAVF) Precludes Renal Transplantation Due to Allosensitization

CAVF has been proposed as a superior access conduit in the problem access population. The potential advantage is the reported 80% endothelial cell viability that theoretically leads to fewer thromboses and greater patency. The authors reviewed a series of 20 consecutive patients who received CAVY as access. At 3.1 months postgraft placement, mean panel reactive antibody (PRA) for this group was 77.8%. Retrospective pregraft PRA values were found on seven patients who were on the transplant waiting list, and six of these were found to have been unsensitized ([is less than] 0.05%) prior to CAVF. Mean PRA in these patients post CAVF was 92.3%. The authors concluded that CAVF use can broadly allosensitize recipients, precluding transplantation in the vast majority. Therefore, CAVF should not be used in potential transplant recipients.
Use of Cryopreserved Cadaver Vein Allograft (CAVF) Precludes Renal Transplantation Due to Allosensitization. G. Lipkowitz, B. Benedetto, R. Madden, A. Kurbanov, D. Hull, M. Germain, L. Bow, & M. Miller. [...]